Rockefeller Capital Management
SLDB icon

Rockefeller Capital Management’s Solid Biosciences SLDB Stock Holding History

Rockefeller Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5K Sell
1,947
-642
-25% -$4.87K ﹤0.01% 3742
2026
Q1 		$18.6K Buy
2,589
+2,245
+653% +$14.4K ﹤0.01% 3736
2025
Q4 		$1.94K Buy
344
+244
+244% +$1.32K ﹤0.01% 4327
2025
Q3 		$617 Buy
+100
New +$585 ﹤0.01% 4245

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rockefeller Capital Management's SLDB Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Solid Biosciences (SLDB) stake by 25% in Q2 2026, selling an estimated $4.87K and leaving 1,947 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3742.

Rockefeller Capital Management first reported a position in SLDB in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Rockefeller Capital Management held 1,947 shares of Solid Biosciences worth $19.5K as of Q2 2026.
  • Rockefeller Capital Management sold 642 Solid Biosciences shares in Q2 2026, an estimated $4.87K.
  • Solid Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3742 holding.
  • Rockefeller Capital Management first reported a position in Solid Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.